Effects of Mesenchymal Stem Cell-Derived Secretome on Glycemic Control and Pancreatic Islet Morphology in Streptozotocin-Induced Diabetic Rats
Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia and progressive pancreatic islet dysfunction. The mesenchymal stem cell (MSC)-derived secretome has been investigated as a potential cell-free therapeutic approach because of its reported paracrine, anti-inflammatory, and tissue-reparative effects. This study evaluated the effects of MSC-derived secretome administration on day-28 random blood glucose levels and pancreatic islet morphology in streptozotocin (STZ)-induced diabetic rats. Twenty-one male Sprague–Dawley rats were randomly assigned to three groups: negative control, diabetic control, and secretome-treated diabetic groups (n = 7 per group). The treated group received 0.5 mL of umbilical cord MSC-derived secretome intraperitoneally once weekly for three consecutive weeks, beginning on day 8 after STZ induction. Day-28 random blood glucose levels were analyzed using the Kruskal–Wallis test followed by Bonferroni-adjusted Mann–Whitney U tests. Pancreatic islet area was analyzed using one-way analysis of variance followed by Bonferroni-adjusted post hoc comparisons. Day-28 random blood glucose was lower in the secretome-treated diabetic group than in the diabetic control group (263.71 ± 122.29 vs. 423.00 ± 36.89 mg/dL; adjusted p = 0.0378). Pancreatic islet area differed among the three groups (p = 0.0043), with a significant difference between the negative control and diabetic control groups (p = 0.004). The difference between the diabetic control and secretome-treated diabetic groups was not statistically significant (p = 0.061). Qualitative examination of hematoxylin and eosin (H&E)-stained sections suggested better-preserved islet morphology in the treated group. These findings indicate lower day-28 random blood glucose following secretome treatment, while evidence for an improvement in pancreatic islet area remains inconclusive. The study does not establish β-cell regeneration.
Keywords: mesenchymal stem cell-derived secretome; streptozotocin-induced diabetes; random blood glucose; pancreatic islet morphology; Sprague–Dawley rats.
Full Text:
PDFReferences
HOSSAIN J., AL-MAMUN M., and ISLAM R. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused[J]. Health Science Reports, 2024, 7(3): e2004. https://doi.org/10.1002/hsr2.2004.
MŁYNARSKA E., CZARNIK W., DZIEŻA N., et al. Type 2 diabetes mellitus: New pathogenetic mechanisms, treatment and the most important complications[J]. International Journal of Molecular Sciences, 2025, 26(3): 1094. https://doi.org/10.3390/ijms26031094.
SUN H., SAEEDI P., KARURANGA S., et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Research and Clinical Practice, 2022, 183: 109119. https://doi.org/10.1016/j.diabres.2021.109119.
SOEATMADJI D.W., ROSANDI R., SARASWATI M.R., et al. Clinicodemographic profile and outcomes of type 2 diabetes mellitus in the Indonesian cohort of DISCOVER: A 3-year prospective cohort study[J]. Journal of the ASEAN Federation of Endocrine Societies, 2023, 38(1): 68-74. https://doi.org/10.15605/jafes.038.01.10.
DLUDLA P.V., MABHIDA S.E., ZIQUBU K., et al. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress[J]. World Journal of Diabetes, 2023, 14(3): 130-146. https://doi.org/10.4239/wjd.v14.i3.130.
MARGIANA R., MARKOV A., ZEKIY A.O., et al. Clinical application of mesenchymal stem cell in regenerative medicine: A narrative review[J]. Stem Cell Research & Therapy, 2022, 13(1): 366. https://doi.org/10.1186/s13287-022-03054-0.
GAO S., ZHANG Y., LIANG K., et al. Mesenchymal stem cells (MSCs): A novel therapy for type 2 diabetes[J]. Stem Cells International, 2022, 2022: 8637493. https://doi.org/10.1155/2022/8637493.
WANG M., SONG L., STRANGE C., et al. Therapeutic effects of adipose stem cells from diabetic mice for the treatment of type 2 diabetes[J]. Molecular Therapy, 2018, 26(8): 1921-1930. https://doi.org/10.1016/j.ymthe.2018.06.013.
DEWI R.P. Effect of hypoxia mesenchymal cell secretome administration on pancreatic beta cell count in type 1 diabetic rat model[D]. Semarang: Universitas Islam Sultan Agung, 2021. https://repository.unissula.ac.id/30547/.
GALICIA-GARCÍA U., BENITO-VICENTE A., JEBARI S., et al. Pathophysiology of type 2 diabetes mellitus[J]. International Journal of Molecular Sciences, 2020, 21(17): 6275. https://doi.org/10.3390/ijms21176275.
AKINLADE O.M., OWOYELE B.V., and SOLADOYE A.O. Streptozotocin-induced type 1 and 2 diabetes in rodents: A model for studying diabetic cardiac autonomic neuropathy[J]. African Health Sciences, 2021, 21(2): 719-727. https://doi.org/10.4314/ahs.v21i2.30.
GHASEMI A., and JEDDI S. Streptozotocin as a tool for induction of rat models of diabetes: A practical guide[J]. EXCLI Journal, 2023, 22: 274-294. https://doi.org/10.17179/excli2022-5720.
GILETA A.F., FITZPATRICK C.J., CHITRE A.S., et al. Genetic characterization of outbred Sprague Dawley rats and utility for genome-wide association studies[J]. PLoS Genetics, 2022, 18(5): e1010234. https://doi.org/10.1371/journal.pgen.1010234.
FOO J.B., LOOI Q.H., CHONG P.P., et al. Comparing the therapeutic potential of stem cells and their secretory products in regenerative medicine[J]. Stem Cells International, 2021, 2021: 2616807. https://doi.org/10.1155/2021/2616807.
RIBOT J., CALIAPEROUMAL G., PAQUET J., et al. Type 2 diabetes alters mesenchymal stem cell secretome composition and angiogenic properties[J]. Journal of Cellular and Molecular Medicine, 2017, 21(2): 349-363. https://doi.org/10.1111/jcmm.12969.
Refbacks
- There are currently no refbacks.
